OncoMatch/Clinical Trials/NCT06564038
A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
Is NCT06564038 recruiting? Yes, currently enrolling (Sep 2026). This Phase 1/2 trial studies multiple treatments for chronic lymphocytic leukaemia.
Treatment: Surovatamig · Prednisone (or equivalent) · Rituximab · Cyclophosphamide · Vincristine · Doxorubicin · Acalabrutinib — The purpose of this study is to assess the safety and efficacy of surovatamig (formerly AZD0486) administered as monotherapy or in combination with other anticancer agents in participants with hematological malignancies
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Targeted therapy
Chemotherapy
Other
Cancer type
Chronic Lymphocytic Leukemia
Non-Hodgkin Lymphoma
Diffuse Large B-Cell Lymphoma
Biomarker criteria
Required: CD19 expression (testing required; no eligibility threshold specified)
Disease stage
Required: Stage II, III, IV
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Must have received: systemic therapy — CLL/SLL
Cohort 1A and 1C: at least 2 prior lines of systemic therapy for CLL/SLL
Must have received: systemic therapy — CLL/SLL
Cohort 1B: at least 1 prior line of therapy and is bruton tyrosine kinase inhibitor (BTKi)-sensitive
Must have received: systemic therapy including BTKi — MCL
Cohort 2A and 2C: Relapse or progressed after 2 or more lines of therapy including BTKi
Must have received: systemic therapy — B-NHL
R/R B-NHL after at least 1 prior lines of systemic therapy
Lab requirements
Cardiac function
left ventricular ejection fraction (lvef) ≥50%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Research Site · Boston, Massachusetts
- Research Site · Hackensack, New Jersey
- Research Site · New Brunswick, New Jersey
- Research Site · New York, New York
- Research Site · New York, New York
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06564038 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received systemic therapy and systemic therapy.
Does this trial require CD19?
Yes, CD19 expression is a required biomarker for enrollment.
What disease stage is eligible?
Stage II or III or IV is required.
Is there an age limit?
Yes. Patients must be 79 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify